Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa

Int J Tuberc Lung Dis. 2008 Jan;12(1):99-104.

Abstract

Setting: The epidemiology of extensively drug-resistant tuberculosis (XDR-TB), an emerging threat to TB control, is not well understood.

Objective: To gain insight into the genotypic population structure of XDR Mycobacterium tuberculosis strains in South Africa using a molecular approach and thereby determine whether XDR-TB is mainly acquired or transmitted.

Design: Sputum isolates from patients with multidrug-resistant tuberculosis (MDR-TB) were submitted to the National Referral Laboratory for second-line drug susceptibility testing. The XDR-TB isolates were spoligotyped and these data were compared to the geographic origin of the isolate.

Results: Of the 699 MDR-TB isolates submitted for testing between June 2005 and December 2006, 101 (17%) patients had a culture that was resistant to either ofloxacin or kanamycin, and 41 (6%) were resistant to both drugs (XDR-TB). Spoligotyping of the XDR-TB isolates identified 17 genotypes. As a result of the high genotypic diversity and geographical distribution, we estimate that between 63% and 75% of cases developed XDR-TB through acquisition.

Conclusion: Acquisition of extensive drug resistance appears to be the primary mechanism driving the XDR-TB epidemic in South Africa. This urgent TB control issue has to be addressed to prevent the spread of this potentially incurable disease.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use
  • DNA, Bacterial / analysis*
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Extensively Drug-Resistant Tuberculosis / drug therapy
  • Extensively Drug-Resistant Tuberculosis / epidemiology
  • Extensively Drug-Resistant Tuberculosis / microbiology*
  • Genotype
  • Humans
  • Kanamycin / therapeutic use
  • Mycobacterium tuberculosis / classification
  • Mycobacterium tuberculosis / genetics*
  • Ofloxacin / therapeutic use
  • Phenotype
  • South Africa / epidemiology
  • Sputum / microbiology

Substances

  • Antitubercular Agents
  • DNA, Bacterial
  • Kanamycin
  • Ofloxacin